Any Carolina Chagas-Almeida

Any Carolina Chagas-Almeida

Auto-generated profile, based on publicly available information

Any Carolina Chagas-Almeida

Universidade Estadual de Maringá

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AAAna Paula Ames-Sibin
Ana Paula Ames-Sibin
ACAny C. Chagas
Any C. Chagas
SFSabrina Barbosa de Souza Ferreira
Sabrina Barbosa de Souza Ferreira
Filipa MandimFilipa Mandim
Filipa Mandim
Tiane Cristine FinimundyTiane Cristine Finimundy
Tiane Cristine Finimundy
JCJurandir F. Comar
Jurandir F. Comar

1 January 2026 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
CBC.C.O. Bernardo
C.C.O. Bernardo
LCL. Casagrande
L. Casagrande
MCM.F.T. Carvalho
M.F.T. Carvalho
SSS.S. Sestak
S.S. Sestak
MSM.L.M. Sergio
M.L.M. Sergio
RBRoberto Bazotte
Roberto Bazotte
We investigated the potential of the association between microencapsulated quercetin (MEQ) and the probiotic Bifidobacterium animalis in 1,2-dimethylhydrazine (DMH)-induced colorectal cancer (CRC) in Wistar rats with a focus on hepatic alterations and liver lobar heterogeneity. The rats were divided into 5 groups: control (C), CRC (CR), CRC treated with MEQ (CRQ), CRC treated with the probiotic (CRP), and CRC treated with MEQ + probiotic (CRQP). DMH (40 mg/kg) was administered intraperitoneally twice weekly for two weeks. MEQ (10 mg/kg) and the probiotic (5×107 colony forming units) were administered by gavage for 13 weeks. The liver was evaluated by histomorphometry and redox state analyses. CRC was confirmed by aberrant crypt foci in 100% of the DMH animals. The CR group showed increased hepatosomatic index (HSI) and lobe-specific cellular hypertrophy. The treatments reduced the HSI, with the association MEQ + probiotic being the most effective in preventing the physiopathological process associated with CRC. Deep learning-assisted cell quantification revealed a reduction of mononucleated hepatocytes in the CR group, a condition abolished by all treatments. DMH induced asymmetric glycogen accumulation and extracellular matrix remodeling, which were modulated by MEQ and the probiotic. Redox state analysis showed thiol depletion in the caudate lobe, where the quadrate lobe underwent lipid peroxidation and catalase inhibition. The treatments reestablished thiol levels and catalase activity in both lobes, thereby confirming antioxidant and hepatoprotective properties. In conclusion, the association of MEQ and probiotic exhibited lobar heterogeneity in attenuating hepatic damage reinforcing the importance of liver lobar analysis in the therapeutic evaluation of carcinogenesis.

23 December 2025 in Arquivos do Mudi
Verified
Journal Article
Open access
ACAny Carolina Chagas-Almeida
Any Carolina Chagas-Almeida
DSDébora de Mello Gonçales Sant’aNa
Débora de Mello Gonçales Sant’aNa
Introdução: o transtorno de déficit de atenção e hiperatividade (TDAH) é um distúrbio do neurodesenvolvimento caracterizado por desatenção, impulsividade e hiperatividade, impactando o desempenho social e acadêmico. O tratamento convencional inclui fármacos estimulantes e não estimulantes, além da terapia cognitivo-comportamental, porém os efeitos colaterais podem limitar a adesão. Objetivo: revisar a literatura sobre o uso do canabidiol (CBD) no tratamento do TDAH. Métodos: revisão narrativa da literatura em bases científicas, incluindo estudos experimentais e clínicos sobre os efeitos do CBD em modelos animais e humanos. Resultados: estudos em animais demonstraram redução da hiperatividade e melhora do comportamento social, sem alteração significativa da atenção. Em um ensaio clínico com adultos, o CBD apresentou melhora na impulsividade e tendência à melhora da desatenção. Conclusão: embora os resultados sejam promissores, são necessárias mais pesquisas controladas para confirmar a eficácia e segurança do canabidiol no TDAH.